EUVIMEDEUVIMED entdecken
Open Access

Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors

Leo Mascarenhas iD, Steven G DuBois iD, Catherine M Albert iD, Stefan Bielack iD, Daniel Orbach iD, Noah Federman, Birgit Geoerger iD, Ramamoorthy Nagasubramanian, Yizhou Zhang iD, Julia Chisholm iD, Soledad Gallego Melcon iD, Hiroaki Goto und 12 weitere

Journal of Clinical Oncology · 2025-04 · 43 (10) · 1180-1187

DOI: 10.1200/jco.24.00848 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2025-04. Verfasst von Leo Mascarenhas und 23 weiteren Autor:innen. Beteiligte Einrichtung: Cedars Sinai Medical Center, Los Angeles, CA. Hauptthemen laut MEDLINE: Pyrazoles, Pyrimidines, Sarcoma, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with efficacy in children with TRK fusion tumors. We evaluated patient outcomes after elective discontinuation of larotrectinib in the absence of disease progression in a protocol-defined wait-and-see subset analysis of eligible patients where treatment resumption with larotrectinib was allowed if disease progressed. We also assessed the safety and efficacy of larotrectinib in all pediatric patients with sarcoma. This cohort included 91 patients (younger than 18 years) from two clinical trials: infantile fibrosarcoma (49), other soft tissue sarcomas or related mesenchymal tumors (41), and bone sarcoma (1). Treatment-related adverse events were of maximum grade 1 or 2 in 25% and 25% of patients, respectively. The overall response rate was 87% (95% CI, 78 to 93). In the wait-and-see analysis, 47 patients discontinued larotrectinib. Median time from discontinuation to disease progression was not reached. Sixteen patients had tumor progression during the wait-and-see period. All 16 patients resumed larotrectinib, and 15 (94%) achieved disease control, with 11 objective responses. Larotrectinib continues to demonstrate durable responses with favorable safety in children with TRK fusion sarcomas. Treatment discontinuation is feasible in select patients with objective response and clinical benefit noted in those who have disease progression after elective treatment discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesPyrimidinesSarcomaOncogene Proteins, FusionReceptor, trkAProtein Kinase InhibitorsSoft Tissue NeoplasmsHumansChildMaleFemaleAdolescentChild, PreschoolInfant

Substanzen

larotrectinibPyrazolesPyrimidinesOncogene Proteins, FusionReceptor, trkAProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Cedars Sinai Medical Center, Los Angeles, CA.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA.
  • Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA.
  • Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentrum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany.
  • SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France.
  • David Geffen School of Medicine, University of California, Los Angeles, CA.

ORCID-Profile: Leo Mascarenhas, Steven G DuBois, Catherine M Albert, Stefan Bielack, Daniel Orbach, Birgit Geoerger, Yizhou Zhang, Julia Chisholm, Soledad Gallego Melcon, Daniel A Morgenstern, Alberto S Pappo, Johannes H Schulte, Neerav Shukla, Christian Michel Zwaan, Cornelis M van Tilburg, Theodore W Laetsch

Förderung

  • NCI NIH HHS

Zitieren

APA

Mascarenhas, L., DuBois, S. G., Albert, C. M., Bielack, S., Orbach, D., Federman, N., Geoerger, B., Nagasubramanian, R., Zhang, Y., Chisholm, J., Gallego Melcon, S., Goto, H., Morgenstern, D. A., Owens, C., Pappo, A. S., Perreault, S., Schulte, J. H., Shukla, N., Zwaan, C. M., …, & Laetsch, T. W. (2025). Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. Journal of Clinical Oncology, 43(10), 1180-1187. https://doi.org/10.1200/jco.24.00848

Vancouver

Mascarenhas L, DuBois SG, Albert CM, Bielack S, Orbach D, Federman N, et al. Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. Journal of Clinical Oncology. 2025;43(10):1180-1187. doi:10.1200/jco.24.00848

BibTeX
@article{Mascarenhas2025,
  author = {Mascarenhas, Leo and DuBois, Steven G and Albert, Catherine M and Bielack, Stefan and Orbach, Daniel and Federman, Noah and Geoerger, Birgit and Nagasubramanian, Ramamoorthy and Zhang, Yizhou and Chisholm, Julia and Gallego Melcon, Soledad and Goto, Hiroaki and Morgenstern, Daniel A and Owens, Cormac and Pappo, Alberto S and Perreault, Sébastien and Schulte, Johannes H and Shukla, Neerav and Zwaan, Christian Michel and Neu, Natascha and Bernard-Gauthier, Vadim and De La Cuesta, Esther and van Tilburg, Cornelis M and Laetsch, Theodore W},
  title = {Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {10},
  pages = {1180--1187},
  doi = {10.1200/jco.24.00848}
}
Kostenlos starten →